Rosacea Therapy

  • Gerd Plewig
  • Bodo Melnik
  • WenChieh Chen


Avoidance of rosacea trigger factors and appropriate skin care such as sunscreens and moisturizing agents are important first steps for rosacea treatment and prevention. Pharmacologic interventions range from topical to systemic medications, with the ideal medication choice dependent on the symptoms and severity of each individual patient. The endoplasmic reticulum (ER) stress model of rosacea pathogenesis (see Chap.  8) sheds new light on preventive and therapeutic interventions controlling this chronic skin disease. This chapter shows that prophylactic measures and pharmacological interventions synergize in attenuating enhanced ER stress of rosacea skin.


  1. Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283:162–6.PubMedGoogle Scholar
  2. Akamatsu H, Asada M, Komura J, et al. Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline. Acta Derm Venereol. 1992;72:178–9.PubMedGoogle Scholar
  3. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47:284–8.PubMedGoogle Scholar
  4. Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. Am J Clin Dermatol. 2010;11:79–87.PubMedGoogle Scholar
  5. Anderson MS, Nadkarni A, Cardwell LA, et al. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2017;11:1143–50.PubMedPubMedCentralGoogle Scholar
  6. Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthalmol. 2015;8:544–9.PubMedPubMedCentralGoogle Scholar
  7. Bakar O, Demirçay Z, Yuksel M, et al. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol. 2007;32:197–200.PubMedGoogle Scholar
  8. Balakirski G, Baron JM, Megahed M. Morbus Morbihan als Sonderform der Rosazea: Einblick in die Pathogenese und neue Therapieoptionen. Hautarzt. 2013;64:884–6.PubMedGoogle Scholar
  9. Bassi A, Campolmi P, Dindelli M, et al. Laser surgery in rhinophyma. G Ital Dermatol Venereol. 2016;151:9–16.PubMedGoogle Scholar
  10. Borovaya A, Dombrowski Y, Zwicker S, et al. Isotretinoin therapy changes the expression of antimicrobial peptides in acne vulgaris. Arch Dermatol Res. 2014;306:689–700.PubMedGoogle Scholar
  11. Castro ML, Franco GC, Branco-de-Almeida LS, et al. Downregulation of proteinase-activated receptor-2, interleukin-17, and other proinflammatory genes by subantimicrobial doxycycline dose in a rat periodontitis model. J Periodontol. 2016;87:203–10.PubMedGoogle Scholar
  12. Chakraborty S, Elvezio V, Kaczocha M, et al. Presynaptic inhibition of transient receptor potential vanilloid type 1 (TRPV1) receptors by noradrenaline in nociceptive neurons. J Physiol. 2017;595:2639–60.PubMedPubMedCentralGoogle Scholar
  13. Ci X, Li H, Yu Q, et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol. 2009;23:449–55.PubMedGoogle Scholar
  14. Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69:570–7.PubMedPubMedCentralGoogle Scholar
  15. Crispin MK, Hruza GJ, Kilmer SL. Lasers and energy-based devices in men. Dermatol Surg. 2017;43(Suppl 2):S176–84.PubMedGoogle Scholar
  16. Deeks ED. Ivermectin: a review in rosacea. Am J Clin Dermatol. 2015;16:447–52.PubMedGoogle Scholar
  17. Del Rosso JQ. Topical α-agonist therapy for persistent facial erythema of rosacea and the addition of oximetazoline to the treatment armamentarium: where are we now? J Clin Aesthet Dermatol. 2017;10:28–32.PubMedPubMedCentralGoogle Scholar
  18. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791–802.PubMedGoogle Scholar
  19. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014a;93:18–28.PubMedGoogle Scholar
  20. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014b;93:134–8.PubMedGoogle Scholar
  21. Di Nardo A, Holmes AD, Muto Y, et al. Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial. J Am Acad Dermatol. 2016;74:1086–92.PubMedGoogle Scholar
  22. Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol. 2012;132:2198–205.PubMedPubMedCentralGoogle Scholar
  23. Doan S, Gabison E, Chiambaretta F, et al. Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis. J Ophthalmic Inflamm Infect. 2013;3:38.PubMedPubMedCentralGoogle Scholar
  24. Draelos ZD. Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel. Cutis. 2004;74:257–60.PubMedGoogle Scholar
  25. El-Heis S, Buckley DA. Rosacea-like eruption due to topical pimecrolimus. Dermatol Online J. 2015;21:5.Google Scholar
  26. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641–5.PubMedGoogle Scholar
  27. Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166:633–41.PubMedPubMedCentralGoogle Scholar
  28. Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;2:650–6.Google Scholar
  29. Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148–55.PubMedGoogle Scholar
  30. Goetze S, Hiernickel C, Elsner P. Phototoxicity of doxycycline: a systematic review on clinical manifestations, frequency, cofactors, and prevention. Skin Pharmacol Physiol. 2017;30:76–80.PubMedGoogle Scholar
  31. Gold LS, Papp K, Lynde C, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16:909–16.PubMedGoogle Scholar
  32. Gollnick H, Blume-Peytavi U, Szabó EL, et al. Systemisches Isotretinoin in der Behandlung der Rosazea—Doxycyclin- und plazebokontrollierte, randomisierte Studie. J Dtsch Dermatol Ges. 2010;8:505–15.PubMedGoogle Scholar
  33. Gonser LI, Gonser CE, Deuter C, et al. Systemic therapy of ocular and cutaneous rosacea in children. J Eur Acad Dermatol Venereol. 2017;31:1732–8.PubMedGoogle Scholar
  34. Hofmann MA, Lehmann P. Physikalische Methoden zur Behandlung der Rosazea. J Dtsch Dermatol Ges. 2016;14(Suppl 6):38–43.PubMedGoogle Scholar
  35. Holmes AD, Waite KA, Chen MC, et al. Dermatological adverse events associated with topical brimonidine gel 0.33% in subjects with erythema of rosacea: a retrospective review of clinical studies. J Clin Aesthet Dermatol. 2015;8:29–35.PubMedPubMedCentralGoogle Scholar
  36. Hoover RM, Erramouspe J. Role of topical oxymetazoline for management of erythematotelangiectatic rosacea. Ann Pharmacother. 2018;52:263–7.PubMedGoogle Scholar
  37. Hoyt JC, Ballering J, Numanami H, et al. Doxycycline modulates nitric oxide production in murine lung epithelial cells. J Immunol. 2006;176:567–72.PubMedGoogle Scholar
  38. Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea. Arch Dermatol. 2011;147:1258–60.PubMedGoogle Scholar
  39. Hu SW, Robinson M, Meehan SA, Cohen DE. Morbihan disease. Dermatol Online J. 2012;18:27.PubMedGoogle Scholar
  40. Ilkovitch D, Pomerantz RG. Brimonidine effective but may lead to significant rebound erythema. J Am Acad Dermatol. 2014;70:e109–10.PubMedGoogle Scholar
  41. Iovieno A, Lambiase A, Micera A, et al. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol. 2009;19:708–16.PubMedGoogle Scholar
  42. Jackson JM, Knuckles M, Minni JP, et al. The role of brimonidine tartrate gel in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2015;8:529–38.PubMedPubMedCentralGoogle Scholar
  43. Jang YH, Sim JH, Kang HY, et al. Immunohistochemical expression of matrix metalloproteinases in the granulomatous rosacea compared with the non-granulomatous rosacea. J Eur Acad Dermatol Venereol. 2011;25:544–8.PubMedGoogle Scholar
  44. Jones DA. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthet Dermatol. 2009;2:26–30.PubMedPubMedCentralGoogle Scholar
  45. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132:1435–42.PubMedPubMedCentralGoogle Scholar
  46. Kim MB, Kim GW, Park HJ, et al. Pimecrolimus 1% cream for the treatment of rosacea. J Dermatol. 2011a;38:1135–9.PubMedGoogle Scholar
  47. Kim JH, Oh YS, Choi EH. Oral azithromycin for treatment of intractable rosacea. J Korean Med Sci. 2011b;26:694–69.PubMedPubMedCentralGoogle Scholar
  48. Kim M, Kim J, Jeong SW, et al. Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. Exp Dermatol. 2017;26:1143–5.PubMedGoogle Scholar
  49. Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009a;22:287–94.PubMedGoogle Scholar
  50. Korting HC, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009b;23:876–82.PubMedGoogle Scholar
  51. Layton AM, Schaller M, Homey B, et al. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol. 2015;29:2405–10.PubMedPubMedCentralGoogle Scholar
  52. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol. 2005;174:2467–70.PubMedGoogle Scholar
  53. Liu RH, Smith MK, Basta SA, Farmer ER. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142:1047–52.PubMedGoogle Scholar
  54. Longo CM, Adam AP, Wladis EJ. Rosacea and the eye: a recent review. Expert Rev Ophthalmol. 2018;13:57–64.Google Scholar
  55. Lowe NJ. Use of topical metronidazole in moderate to severe rosacea. Adv Ther. 2003;20:177–90.PubMedGoogle Scholar
  56. Lowe E, Lim S. Paradoxical erythema reaction of long-term topical brimonidine gel for the treatment of facial erythema of rosacea. J Drugs Dermatol. 2016;15:763–5.PubMedGoogle Scholar
  57. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40:961–5.PubMedGoogle Scholar
  58. Mantelli F, Di Zazzo A, Sacchetti M, et al. Topical azithromycin as a novel treatment for ocular rosacea. Ocul Immunol Inflamm. 2013;21:371–7.PubMedGoogle Scholar
  59. Melnik BC. Endoplasmic reticulum stress: key promoter of rosacea pathogenesis. Exp Dermatol. 2014;23:868–73.PubMedGoogle Scholar
  60. Melnik BC. Rosacea: the blessing of the Celts—an approach to pathogenesis through translational research. Acta Derm Venereol. 2016;96:147–56.PubMedGoogle Scholar
  61. Micali G, Gerber PA, Lacarrubba F, Schäfer G. Improving treatment of erythematotelangiectatic rosacea with laser and/or topical therapy through enhanced discrimination of its clinical features. J Clin Aesthet Dermatol. 2016;9:30–9.PubMedPubMedCentralGoogle Scholar
  62. Mizoguchi S, Iwanishi H, Arita R, et al. Ocular surface inflammation impairs structure and function of meibomian gland. Exp Eye Res. 2017;163:78–84.PubMedPubMedCentralGoogle Scholar
  63. Modi S, Harting M, Rosen T. Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic. J Drugs Dermatol. 2008;7:898–9.PubMedGoogle Scholar
  64. Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63:130–45.PubMedGoogle Scholar
  65. Morizane S, Yamasaki K, Kabigting FD, Gallo RL. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J Invest Dermatol. 2010;130:1297–306.PubMedPubMedCentralGoogle Scholar
  66. Narayanan S, Hünerbein A, Getie M, et al. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol. 2007;59:1125–30.PubMedGoogle Scholar
  67. Nikolowski J, Plewig G. Orale Behandlung der Rosazea mit 13-cis-Retinsäure. Hautarzt. 1981;32:575–84.PubMedGoogle Scholar
  68. Ong HS, Patel KV, Dart JK, Praestegaard M. Topical cyclosporin A as a steroid-sparing agent for ocular rosacea. Acta Ophthalmol. 2017;95:e158–9.PubMedGoogle Scholar
  69. Patel NU, Shukla S, Zaki J, Feldman SR. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. Expert Rev Clin Pharmacol. 2017;10:1049–54.PubMedGoogle Scholar
  70. Pfeffer I, Borelli C, Zierhut M, Schaller M. Behandlung der Ophthalmo-Rosazea mit 40 mg Doxycyclin in teilretardierter Form. J Dtsch Dermatol Ges. 2011;9:904–7.PubMedGoogle Scholar
  71. Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatolog Treat. 2018;29:310–3.PubMedGoogle Scholar
  72. Rademaker M. Very low-dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients. Australas J Dermatol. 2018;59:26–30.PubMedGoogle Scholar
  73. Reinholz M, Tietze JK, Kilian K, et al. Rosacea—S1 guideline. J Dtsch Dermatol Ges. 2013;11:768–80.PubMedGoogle Scholar
  74. Sanchez J, Somolinos AL, Almodóvar PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53:791–7.PubMedGoogle Scholar
  75. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal. 2009;11:2409–27.PubMedGoogle Scholar
  76. Schaller M, Dirschka T, Kemény L, et al. Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded ATTRACT study. Dermatol Ther (Heidelb). 2016;6:427–36.Google Scholar
  77. Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017;31:1907–11.PubMedGoogle Scholar
  78. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26:651–9.PubMedGoogle Scholar
  79. Schweinzer K, Kofler L, Spott C, et al. Surgical treatment of rhinophyma: experience from a German cohort of 70 patients. Eur J Dermatol. 2017;27:281–5.PubMedGoogle Scholar
  80. Siddiqui K, Stein Gold L, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis. Springerplus. 2016;5:1151.PubMedPubMedCentralGoogle Scholar
  81. Sobolewska B, Doycheva D, Deuter C, et al. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33:257–60.PubMedGoogle Scholar
  82. Steinhoff M, Schmelz M, Schauber J. Facial erythema of rosacea—aetiology, different pathophysiologies and treatment options. Acta Derm Venereol. 2016a;96:579–86.PubMedGoogle Scholar
  83. Steinhoff M, Vocanson M, Voegel JJ, et al. Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments. Adv Ther. 2016b;33:1481–501.PubMedPubMedCentralGoogle Scholar
  84. Strand M, Bergqvist G, Griffith S, Bergqvist E. The effect of recurrent pulsed dye laser treatments in rosacea patients. J Cosmet Laser Ther. 2017;19:160–4.PubMedGoogle Scholar
  85. Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172:1103–10.PubMedGoogle Scholar
  86. Teraki Y, Hitomi K, Sato Y, Izaki S. Tacrolimus-induced rosacea-like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology. 2012;224:309–14.PubMedGoogle Scholar
  87. Thibaut de Ménonville S, Rosignoli C, Soares E, et al. Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models. Dermatol Ther (Heidelb). 2017;7:213–25.Google Scholar
  88. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8:639–48.PubMedGoogle Scholar
  89. Tong LX, Moore AY. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert Rev Clin Pharmacol. 2014;7:567–77.PubMedGoogle Scholar
  90. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol. 2015;72:761–70.PubMedGoogle Scholar
  91. van der Linden MMD, van Ratingen AR, van Rappard DC, et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol. 2017;176:1465–74.PubMedGoogle Scholar
  92. van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev. 2015;(4):CD003262.Google Scholar
  93. Webster G, Schaller M. Ocular rosacea: a dermatologic perspective. J Am Acad Dermatol. 2013;69(6 Suppl 1):S42–3.PubMedGoogle Scholar
  94. Wirth PJ, Henderson Berg MH, Sadick N. Real-world efficacy of azelaic acid 15% gel for the reduction of inflammatory lesions of rosacea. Skin Therapy Lett. 2017;22:5–7.PubMedGoogle Scholar
  95. Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79:73–80.PubMedGoogle Scholar
  96. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(4 Suppl):3–11.PubMedGoogle Scholar
  97. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131:688–97.PubMedGoogle Scholar
  98. Zhang X, Song Y, Xiong H, et al. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol. 2009;9:354–9.PubMedGoogle Scholar
  99. Zhang L, Su Z, Zhang Z, et al. Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease. JAMA Ophthalmol. 2015;133:1117–23.PubMedPubMedCentralGoogle Scholar
  100. Zip CM. Innovative use of topical metronidazole. Dermatol Clin. 2010;28:525–34.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gerd Plewig
    • 1
  • Bodo Melnik
    • 2
  • WenChieh Chen
    • 3
  1. 1.Department of Dermatology and AllergyLudwig-Maximilian-University MunichMunichGermany
  2. 2.Department of Dermatology, Environmental Medicine and Health TheoryUniversity of OsnabrückOsnabrückGermany
  3. 3.Department of Dermatology and AllergyTechnical University of MunichMunichGermany

Personalised recommendations